Abstract
Background: The susceptibility of breast cancer is largely affected by the metabolic capacity of breast tissue. This ability depends in part on the expression profile of cytochrome P450 (CYPs). CYPs are a superfamily of enzymes with related catalysis to endogenous and exogenous bioactive substances, including xenobiotic metabolism, drugs, and some endogenous substances metabolism which activate cells and stimulate cell signaling pathways, such as arachidonic acid metabolism, steroid metabolism, fatty acid metabolism. Interestingly, CYP was electively expressed in different tumors, and mediated the metabolic activation of multiple carcinogens and participated in the activation and deactivation of tumor therapeutic drugs. However, the biological action of cytochrome P450 2U1 (CYP2U1) in breast carcinoma is little understood so far.Methods: To investigate the biological value of CYP2U1 in breast carcinoma, we performed immunohistochemical (IHC) analysis and survival analysis based on clinico-pathological data of breast cancer.Results: IHC analysis showed that the abundance of CYP2U1 protein was inversely proportional to the state of estrogen receptor(ER) (P < 0.05), and the lower the degree of tumor differentiation, the higher the protein abundance (P < 0.001). Additionally, compared with luminal tumors, the CYP2U1 protein content was more abundant in triple negative breast cancer (P < 0.05). Importantly, survival analysis showed that higher CYP2U1 protein levels predicted poor 5-year overall survival rate (P < 0.01), 5-year disease-free survival rate (P < 0.05), and 5-year metastatic-free survival rate (P < 0.01) for the entire enrolled breast cancer patients.Conclusions: CYP2U1 is generally closely related to the clinicopathological characteristics and is also an adverse prognostic factor for breast carcinoma patients, indicating that CYP2U1 is engaged in the malignant progression of breast carcinoma.
Highlights
Breast carcinoma is the most generalized type of cancer among women
The results demonstrated that cytochrome P450 2U1 (CYP2U1) was mainly detected in the cytoplasm of breast cancer tissue, while in non-cancer breast tissue, CYP2U1 was mainly located
Our results showed that the protein level of CYP2U1 was distinctly higher in breast carcinoma tissues in comparison with normal tissues (Figure 1B, P < 0.0001)
Summary
Breast carcinoma is the most generalized type of cancer among women. It is one of the prime causes of cancer-related deaths in women and poses a serious threat to public health worldwide [1]. CYP2U1 Is a Prognostic Biomarker of Breast Cancer four different molecular subtypes, containing luminal, HER2enriched, basal-like, and normal-like type [2]. The susceptibility of breast cancer is largely affected by the metabolic capacity of breast tissue. This ability depends in part on the expression profile of cytochrome P450 (CYPs). CYP was electively expressed in different tumors, and mediated the metabolic activation of multiple carcinogens and participated in the activation and deactivation of tumor therapeutic drugs. The biological action of cytochrome P450 2U1 (CYP2U1) in breast carcinoma is little understood so far
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
